TGF-β1 role in uterine leiomyoma and endometrial polyp: an insight to drug-based treatment instead of surgical techniques

Objective Considering the high prevalence of leiomyoma and endometrial polyps, investigating the contributing factors and determining the pathophysiology of these lesions are essential. Target therapy is now an acceptable method for the treatment of some diseases. We aimed to determine the expression of transforming growth factor (TGF)-β1 in endometrial polyps and leiomyomas to discover a drug-based method to overcome surgical treatments. Methods In this cross-sectional study, 55 patients with leiomyoma and 55 patients with polyps were included. Prepared slides from leiomyoma and adjacent myometrium or polyp lesions and adjacent endometrium were obtained and investigated for TGF-β1. Then, data were collected and analyzed using SPSS version 22. Results The mean age of participants was 40.6±5.8 years. Based on their reports, 88.2% (n=97) of patients in the study population had abnormal uterine bleeding with similar distributions among both groups. In contrast, 63.5% of the leiomyoma group did not express TGF-β1. However, in normal myometrium, 23.6% had the highest degree of TGF-β1 expression. Polyp tissue did not show staining for TGF-β1 in any patients. Additionally, 89.1% of non-polypoid endometrium did not express TGF-β1. Normal tissue had a significantly greater amount of TGF-β1 compared to leiomyoma and endometrial polyps. Conclusion TGF-β1 is expressed more prominently in normal myometrium with mostly high-intensity features compared to leiomyoma. Additionally, polyps showed no staining for TGF-β1, while normal endometrium showed a low-density staining pattern.

[1]  S. K. Kato,et al.  Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers: a case control study , 2020, Sao Paulo medical journal = Revista paulista de medicina.

[2]  F. Penault-Llorca,et al.  Role of Hormones in Common Benign Uterine Lesions: Endometrial Polyps, Leiomyomas, and Adenomyosis. , 2020, Advances in experimental medicine and biology.

[3]  R. Markham,et al.  Endometrial polyps: Pathogenesis, sequelae and treatment , 2019, SAGE open medicine.

[4]  T. Lai,et al.  Connective tissue growth factor mediates transforming growth factor β-induced collagen expression in human endometrial stromal cells , 2019, PloS one.

[5]  Yang Shen,et al.  The effect of TGF-β signaling on regulating proliferation of uterine leiomyoma cell via ERα signaling activated by bisphenol A, octylphenol and nonylphenol in vitro , 2018, Journal of cancer research and therapeutics.

[6]  Xiang Tang,et al.  CD4+ T cell imbalance is associated with recurrent endometrial polyps , 2018, Clinical and experimental pharmacology & physiology.

[7]  W. Catherino,et al.  A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma , 2018, BioMed research international.

[8]  Md Soriful Islam,et al.  Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics , 2018, Human reproduction update.

[9]  A. Soliman,et al.  Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey , 2017, Current medical research and opinion.

[10]  Youhua Huang,et al.  Effects of TGF-β on uterine fibroids of women of childbearing age and uterine artery embolization , 2017, Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy.

[11]  A. Al-Hendy,et al.  Hypovitaminosis D and high serum transforming growth factor beta-3: important biomarkers for uterine fibroids risk. , 2016, Fertility and sterility.

[12]  W. Catherino,et al.  Uterine fibroids , 2016, Nature Reviews Disease Primers.

[13]  A. Al-Hendy,et al.  Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy , 2015, Molecular medicine.

[14]  J. Segars,et al.  Liarozole inhibits transforming growth factor-β3--mediated extracellular matrix formation in human three-dimensional leiomyoma cultures. , 2014, Fertility and sterility.

[15]  Concepcion R. Diaz-Arrastia,et al.  2-Methoxyestradiol causes functional repression of transforming growth factor β3 signaling by ameliorating Smad and non-Smad signaling pathways in immortalized uterine fibroid cells. , 2012, Fertility and sterility.

[16]  L. Jing,et al.  Is endometrial polyp formation associated with increased expression of vascular endothelial growth factor and transforming growth factor-beta1? , 2011, European journal of obstetrics, gynecology, and reproductive biology.

[17]  Mostafa El-Feky.  Endometrial polyp , 2011, Radiopaedia.org.

[18]  Md Soriful Islam,et al.  Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. , 2011, Human reproduction update.

[19]  Song Liu,et al.  Expression and clinical significance of the transforming growth factor‐β signalling pathway in endometrial cancer , 2011, Histopathology.

[20]  W. Parker.  Etiology, symptomatology, and diagnosis of uterine myomas. , 2007, Fertility and sterility.

[21]  H. Aytan,et al.  The role of hormone replacement therapy in endometrial polyp formation. , 2005, Maturitas.

[22]  A. Lopata,et al.  Uterine cavity matrix metalloproteinases and cytokines in patients with leiomyoma, adenomyosis or endometrial polyp. , 2003, European journal of obstetrics, gynecology, and reproductive biology.

[23]  N. Chegini,et al.  The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy , 2003, Molecular and Cellular Endocrinology.

[24]  A. Arıcı,et al.  Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-beta1 in human myometrium and leiomyoma. , 2003, American journal of obstetrics and gynecology.

[25]  B. S. Lee,et al.  Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. , 2001, The Journal of clinical endocrinology and metabolism.

[26]  A. Arıcı,et al.  Transforming growth factor-β3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation , 2000 .